

AMENDMENTS

Please enter the following amendments without prejudice or disclaimer.

In the claims:

Please cancel claim 12 without prejudice or disclaimer.

Please amend claims 1, 11, 37 and 40 as follows.

B1
1. (Twice Amended) A method of modulating an immune response to a second antigen in an individual, comprising co-administering to the individual
(i) a complex comprising an immunomodulatory polynucleotide proximately associated with a first antigen and
(ii) a second antigen,
wherein the polynucleotide comprises an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5'-cytosine, guanine-3', wherein the second antigen is not proximately associated with the complex, and wherein the complex is administered in an amount sufficient to modulate an immune response in the individual to the second antigen.

B2
~~11. (Twice Amended) The method of claim 1, wherein the complex and the second antigen are administered at the same site in the individual.~~

B3
37. (Twice Amended) A composition comprising
(i) a complex comprising an immunomodulatory polynucleotide proximately associated with a first antigen and
(ii) a second antigen,

B3
wherein the polynucleotide comprises an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5'-cytosine, guanine-3', wherein the second antigen is not proximately associated with the complex, and wherein the first antigen is a viral conserved polypeptide and the second antigen is a viral variable polypeptide.

B4
40. (Amended) A composition comprising
(i) a complex comprising an immunomodulatory polynucleotide proximately associated with a first antigen and
(ii) a second antigen,
wherein the polynucleotide comprises an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5'-cytosine, guanine-3', wherein the second antigen is not proximately associated with the complex, and wherein the first antigen is an allergen.

Please add new claim 53 as follows.

B5
Sub. C-17
53. (New) A method of modulating an immune response to a second antigen in an individual, comprising co-administering to the individual
(i) a complex comprising an immunomodulatory polynucleotide proximately associated with a first antigen and
(ii) a second antigen,
wherein the polynucleotide comprises an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5'-cytosine, guanine-3', wherein the complex is administered at a site in the individual which is different from the site of administration of the second antigen, and wherein the complex is administered in an amount sufficient to modulate an immune response in the individual to the second antigen.